Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association Between the Development of Subclinical Cardiovascular Disease and Human Immunodeficiency Virus (HIV) Reservoir Markers in People With HIV on Suppressive Antiretroviral Therapy.
Turcotte I, El-Far M, Sadouni M, Chartrand-Lefebvre C, Filali-Mouhim A, Fromentin R, Chamberland A, Jenabian MA, Baril JG, Trottier B, Thomas R, Tremblay CL, Durand M, Chomont N; Canadian HIV and Aging Cohort Study. Turcotte I, et al. Among authors: trottier b. Clin Infect Dis. 2023 Apr 3;76(7):1318-1321. doi: 10.1093/cid/ciac874. Clin Infect Dis. 2023. PMID: 36346439 Free PMC article.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Nelson M, et al. Among authors: trottier b. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12. doi: 10.1097/01.qai.0000185314.56556.c3. J Acquir Immune Defic Syndr. 2005. PMID: 16280694 Clinical Trial.
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigators. Segal-Maurer S, et al. N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542. N Engl J Med. 2022. PMID: 35544387 Clinical Trial.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group. Lazzarin A, et al. Among authors: trottier b. Lancet. 2007 Jul 7;370(9581):39-48. doi: 10.1016/S0140-6736(07)61048-4. Lancet. 2007. PMID: 17617271 Clinical Trial.
A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164).
Walmsley SL, Thorne A, Loutfy MR, LaPierre N, MacLeod J, Harrigan R, Trottier B, Conway B, Hay JR, Singer J, Zarowny D. Walmsley SL, et al. Among authors: trottier b. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25. doi: 10.1097/QAI.0b013e318061b611. J Acquir Immune Defic Syndr. 2007. PMID: 17468667 Clinical Trial.
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group. Lalezari JP, et al. Among authors: trottier b. N Engl J Med. 2003 May 29;348(22):2175-85. doi: 10.1056/NEJMoa035026. Epub 2003 Mar 13. N Engl J Med. 2003. PMID: 12637625 Free article. Clinical Trial.
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP. Reynes J, et al. Among authors: trottier b. AIDS Patient Care STDS. 2007 Aug;21(8):533-43. doi: 10.1089/apc.2006.0174. AIDS Patient Care STDS. 2007. PMID: 17711378 Clinical Trial.
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
Loutfy MR, Ackad N, Antoniou T, Baril JG, Conway B, de Wet J, Trottier B, Kovacs CM, Thompson W, Martel AY, Trottier S, Rouleau D, Shafran SD, Rachlis A, Fraser C, Smaill F, Walmsley SL, Tseng AL, Sampalis JS. Loutfy MR, et al. Among authors: trottier s, trottier b. HIV Clin Trials. 2007 Sep-Oct;8(5):259-68. doi: 10.1310/hct0805-259. HIV Clin Trials. 2007. PMID: 17956827 Clinical Trial.
177 results